326
Participants
Start Date
December 31, 2007
Primary Completion Date
June 30, 2009
Study Completion Date
September 30, 2009
dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg
Dextromethorphan hydrobromide (DM) and quinidine sulfate (Q) capsules (AVP-923 capsules), containing DM 20 mg/ Q 10 mg, taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg
Dextromethorphan hydrobromide (DM) and quinidine sulfate (Q) capsules (AVP-923 capsules), containing DM 30 mg/ Q 10 mg taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
Placebo
Placebo capsules (identical in appearance to AVP-923 capsules being studied in this trial), taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
Mount Sinai Medical Center, New York
Neurological Institute - Columbia Presbyterian Center, New York
Upstate Clinical Research, Albany
Jacobs Neurological Institute, Buffalo
Drexel University - Department of Neurology, Philadelphia
The ALS Center - Penn Neurological Institute - The University of Pennsylvania, Philadelphia
The John Hopkins Universitiy, Baltimore
West Virginia University, Morgantown
Duke Universitiy Medical Center, Durham
Carolinas Medical Center, Charlotte
Neurology Specialists of Decatur of Decatur, Decatur
The ALS Center at Emory University, Atlanta
Mayo Clinic, Jacksonville
University of Miami, Miami
Neuroscience Center, Fort Lauderdale
Suncoast Neuroscience Associates, St. Petersburg
Vanderbilt University, Nashville
University of Kentucky Health Care - Dept. of Neurology, Lexington
Ohio State Universitiy, Columbus
Department of Neurology - The Cleveland Clinic Foundation, Cleveland
University of Michigan, Ann Arbor
Henry Ford Hospital, Detroit
Dean Foundation, Madison
Advanced Neurology Specialists, Great Falls
Consultants in Neurology, Northbrook
Northwestern University, Chicago
St.Louis University - Neuromuscular Clinic, St Louis
Neurology Associates, Lincoln
The Methodist Hospital - Baylor College of Medicine, Houston
University of Texas Health Science Center, San Antonio
Department of Neuropsychiatry - Texas Tech University, Lubbock
University of Colorado at Denver & Health Science Center, Aurora
St. Joseph's Hospital and Medical Center, Phoenix
Neuromuscular Research Center, Scottsdale
Universitiy of Nevada, Las Vegas
UCLA School of Medicine, Los Angeles
Center for Neurologic Study, La Jolla
South Coast Clinical Trials, Anaheim
UCI Medical Center, Irvine
The Forbes Norris MDA/ALS Research Center - California Pacific Medical Center, San Francisco
The ALS Center at UCSF, San Francisco
Oregon Health Science University, Portland
Massachusets General Hospital, Boston
Baystate Medical Center, Springfield
Universitiy of Vermont, Burlington
FACENE, Buenos Aires
IADIN, Buenos Aires
Hospital Italiano, Buenos Aires
INEBA, Buenos Aires
Hospital Ramos Mejia, Buenos Aires
Hospital Britanico, Buenos Aires
Policlinico Bancario, Buenos Aires
FLENI, Buenos Aires
Hospital Militar Regional de Cordoba, Córdoba
Instituto Medico Rodriguez Alfici, Godoy Cruz
Instituto de Neurociencias Rosario, Rosario
Santa Casa de Misericordia de Belo Horizonte, Belo Horizonte
Hospital de Clínicas-UFPR, Curitiba
Hospital da Restauração, Recife
Hospital Universitário Clementino Fraga Filho, Rio de Janeiro
Hospital Moinhos de Vento, Porto Alegre
Hospital das Clínicas da Faculdade de Medicina da Universidade São Paulo, São Paulo
Lead Sponsor
Collaborators (1)
Syneos Health
OTHER
Avanir Pharmaceuticals
INDUSTRY